Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.Read more:
biospace.comBiotechnology